SCAP and fatty liver disease: The results confirmed that the SREBP pathway is required for hepatic steatosis in PTENΔL mice; however, unexpectedly, SCAP/SREBP pathway inhibition markedly exacerbated liver injury, fibrosis, and carcinogenesis in PTENΔL mice.